Group 1 - The core viewpoint of the articles highlights the strong performance of He Yu-B (02256), with its stock price reaching a historical high of 12.89 HKD, reflecting a rise of over 4% [1] - The company reported a revenue of 612 million HKD for the first half of the year, representing a year-on-year growth of 21.5%, and a net profit attributable to shareholders of 328 million HKD, which is a 58.8% increase year-on-year [1] - He Yu plans to implement a share buyback program starting from March 2025, having already repurchased 9.545 million shares, accounting for 1.4% of the total shares issued at the beginning of the year, with a total expenditure of 75.3 million HKD [1] Group 2 - Citigroup believes that He Yu's current valuation is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib, and the potential for differentiated innovative pipelines to achieve external licensing [2] - The bank anticipates a high success rate for the phase III clinical trial of irpagratinib for second-line hepatocellular carcinoma, suggesting that this should be factored into the company's valuation [2] - Key catalysts are expected for He Yu in 2025 and 2026, including the approval and commercialization performance of pimicotinib, the announcement of phase III data for irpagratinib, and updates on multiple candidate drugs such as ABSK043 and ABSK061, along with potential commercial collaborations [2]
港股异动｜和誉-B(02256)涨超4%续创新高 上半年业绩快速增长 花旗称公司现估值偏低